Tiera Liby
Oregon Health & Science University
11 Papers
8 Citations
Tiera Liby is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Cancer & Lapatinib. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease.
Rebecca Smith,Moqing Liu,Tiera Liby,Nora Bayani,Elmar Bucher,Kami E. Chiotti,Daniel S. Derrick,Anne Chauchereau,Laura M. Heiser,Joshi J. Alumkal,Joshi J. Alumkal,Heidi S. Feiler,Peter R. Carroll,James E. Korkola +13 more
TL;DR: This study reinforces the utility of large cell line panels for the study of cancer and identifies several cell lines that represent ideal models to study AR-null cells that have upregulated GR to sustain growth.
Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
TL;DR: The results indicate that 53BP1 is a biomarker of response to anti-PARP therapy in the laboratory, and the DNA damage response gene signature may be used to identify patients who are most likely to respond to PARP inhibition.
Analysis and modeling of cancer drug responses using cell cycle phase-specific rate effects
Sean M. Gross,Farnaz Yar Mohammadi,Crystal Sanchez-Aguila,Paulina J. Zhan,Tiera Liby,Mark A. Dane,Aaron S. Meyer,Laura M. Heiser +7 more
TL;DR: In this paper , a linear chain trick (LCT) computational model was used to capture drug-induced dynamic responses, correctly infers drug effects, and reproduces influences on specific cell cycle phases.
24
A LINCS microenvironment perturbation resource for integrative assessment of ligand-mediated molecular and phenotypic responses
Sean M. Gross,Mark A. Dane,Rebecca Smith,Kaylyn Devlin,Ian McLean,Daniel S. Derrick,Caitlin E. Mills,Kartik Subramanian,Alexandra B K London,Denis Torre,Cemal Erdem,Nicholas J. Lyons,Ted Natoli,Sarah Pessa,Xiaodong Lu,James Mullahoo,Jonathan Z. Li,Miriam Adam,Brook T. Wassie,Moqing Liu,David Kilburn,Tiera Liby,Elmar Bucher,Crystal Sanchez-Aguila,Kenneth Daily,Larsson Omberg,Yunguan Wang,Connor A. Jacobson,Clarence Yapp,Mirra Chung,Dusica Vidovic,Yiling Lu,Stephan C. Schürer,Albert Lee,Ajay S. Pillai,Aravind Subramanian,Malvina Papanastasiou,Ernest Fraenkel,Heidi S. Feiler,Gordon B. Mills,Jake Jaffe,Avi Ma'ayan,Marc R. Birtwistle,Peter K. Sorger,James E. Korkola,Joe W. Gray,Laura M. Heiser +46 more
TL;DR: In this article, the authors generated a comprehensive dataset that catalogs the transcriptional, proteomic, epigenomic and phenotypic responses of MCF10A mammary epithelial cells after exposure to the ligands EGF, HGF, OSM, IFNG, TGFB and BMP2.
Abstract S6-07: Detrimental effects of sequential compared to concurrent treatment of pertuzumab plus T-DM1 in HER2+ breast cancer cell lines
TL;DR: Initial screens showed that concurrent treatment of cells with pertuzumab plus T-DM1 gave significant synergistic interactions in 15/21 cell lines as measured by the median effect method, with combination indices less than 0.5 (and 95% upper confidence levels less than 1.0) for at least one drug concentration.
8